RGLS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States...

Stats
Today's Volume	91 807.00
Average Volume	3.11M
Market Cap	145.33M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.150 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.410
ATR14	$0.00900 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-14	Papadopoulos Stelios	Buy	250 000	Common Stock
2024-01-18	Calsada Crispina	Sell	5 468	Common Stock
2024-01-18	Aker Christopher Ray	Sell	5 468	Common Stock
2024-01-18	Hagan Joseph P	Sell	14 580	Common Stock
2024-01-12	Klassen Preston	Buy	120 000	Stock Option (Right to Buy)

INSIDER POWER
98.54
Last 86 transactions
Buy: 13 400 605 \| Sell: 39 678

Volume Correlation

Long: -0.08 (neutral)

Short: -0.52 (weak negative)

Signal:(59.673) Neutral

Regulus Therapeutics Inc Correlation

10 Most Positive Correlations
STRT	0.824

10 Most Negative Correlations
FORE	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Regulus Therapeutics Inc Correlation - Currency/Commodity

0.28
( neutral )

0.58
( weak )

0.00
( neutral )

0.42
( neutral )

0.54
( weak )

Regulus Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-227 000 (0.00 %)
EPS:	$-1.580

Q4	2023
Revenue:	$0
Gross Profit:	$-76 000.00 (0.00 %)
EPS:	$-0.400

Q3	2023
Revenue:	$0
Gross Profit:	$-56 000.00 (0.00 %)
EPS:	$-0.400

Q2	2023
Revenue:	$0
Gross Profit:	$-47 000.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.